高风险光线乳腺癌中的分子异质性的动力学-从内在到自适应的亚型化

相关实验视频

Updated: May 28, 2025

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Carsten Denkert¹, Sivaramakrishna Rachakonda², Thomas Karn³

¹Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany.

|February 11, 2025

概括

这项研究揭示了化疗后乳腺癌亚型的变化,确定了更好地预测患者预后的新分子组和针对性治疗的高风险组.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
翻译研究是翻译研究.

背景情况:

激素受体阳性/HER2阴性乳腺癌是一个重大的临床挑战.
新辅助化疗可以诱导残留瘤中的分子异质性.
了解这些变化对于改进治疗策略至关重要.

研究的目的:

为了研究乳腺癌中治疗诱导的分子异质性.
在残留瘤中评估内在亚型和新适应性集群的预后价值.
识别分子标记物以改善风险分层.

主要方法:

分析高风险乳腺癌患者的纵向样本 (Penelope-B试验).
在前后新辅助化疗样本中对内在亚型的评估.
转录组分析以定义基于分子变化的适应性集群 (AC-1-5).

主要成果:

内在亚型在治疗前和治疗后都具有预后作用.
在化疗后观察到内在亚型 (LumB到Luma) 的转变.
五个适应性集群 (AC-1-5) 证明了超越传统亚型的预后价值,识别了不同的风险群体.

结论:

疗法在乳腺癌中诱导显著的分子异质性.
适应性集群为改善风险预测提供了精细的分子分类.
这项工作有助于识别高风险患者群体,以进一步开发治疗方法.

关键词:

乳腺癌乳腺癌乳腺癌分子造型分析 (MOP) 是一种分子造型分析.新辅助疗法是一种新辅助疗法.治疗诱导的异质性治疗诱导的异质性

更多相关视频

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...